# Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy

> **NCT01658943** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 137 (actual)

## Conditions studied

- Pancreatic Acinar Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Recurrent Pancreatic Carcinoma
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT01658943
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2016-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01658943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01658943, "Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01658943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*